Abstract
Six normal male volunteers received 0.5 mg label doses of digoxin as (a) a bolus intravenous injection over 2 min, (b) a constant rate intravenous infusion over 1 hr, (c) a constant rate intravenous infusion over 3 hr, and (d) a solution in 5% dextrose given orally. Plasma concentrations of digoxin were measured by radioimmunoassay for a 4 day period and urinary excretion for a 6 day period after the single doses. The mean (coefficient of variation) total areas under the plasma concentration-time curves per 0.5 mg of digoxin were (a) 35.55 (14.8%), (b) 30.20 (27.7%), (c) 25.80 (35.5%), and (d) 15.47 (49.9%); the means differed significantly (0.01>p>0.005). The mean (coefficient of variation) total amounts excreted in the urine as a fraction of the dose were (a) 0.689 (6.31%), (b) 0.517 (20.4%), (c) 0.588 (16.8%), and (d) 0.374 (23.4%); the means differed significantly (p<0.001. Both the total clearance and the nonrenal clearance of digoxin differed significantly with the method of intravenous administration. The slower the rate of input of digoxin to the body, the greater were both the total clearance and the nonrenal clearance of the drug, which strongly suggests nonlinear pharmacokinetics.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
D. J. Greenblatt, D. W. Duhme, J. Koch-Weser, and T. W. Smith. Intravenous digoxin as a bioavailability standard: slow infusion and rapid injection.Clin. Pharmacol. Ther. 15:510–513 (1974).
F. I. Marcus, J. Dickerson, S. Pippin, M. Stafford, and R. Bressler. Digoxin-bioavailability: formulations and rates of infusions.Clin. Pharmacol. Ther. 20:253–259 (1976).
J. G. Wagner, M. R. Hallmark, E. Sakmar, and J. W. Ayres. Sensitive radioimmunoassay for digoxin in plasma and urine.Steroids 29:787–807 (1977).
K.-E. Andersson, L. Nyberg, H. Dencker, and J. Göthlin. Absorption of digoxin in man after oral and intrasigmoid administration studied by portal vein catheterization.Eur. J. Clin. Pharmacol. 9:39–47 (1975).
J. G. Wagner and J. W. Ayres. Bioavailability assessment: methods to estimate total area (AUC 0-∞) and total amount excreted (Ae ∞) and importance of blood and urine sampling scheme with application to digoxin.J. Pharmacokin. Biopharm. 5:533–557 (1977).
D. H. Huffman, C. V. Manion, and D. L. Azarnoff. Absorption of digoxin from different oral preparations in normal subjects during steady state.Clin. Pharmacol. Ther. 16:310–317 (1974).
J. R. Koup, D. J. Greenblatt, W. J. Jusko, T. W. Smith, and J. Koch-Weser. Pharmacokinetics of digoxin in normal subjects after intravenous bolus and infusion doses.J. Pharmacokin. Biopharm. 3:181–192 (1975).
B. L. Lloyd, D. J. Greenblatt, M. D. Allen, J. S. Hermatz, and T. W. Smith. Pharmacokinetics and bioavailability of digoxin capsules, solution and tablets after single and multiple doses.Am. J. Cardiol. 42:129–136 (1978).
E. Lisalo. Clinical pharmacokinetics of digoxin.Clin. Pharmacokin. 2:1–16 (1977).
D. J. Greenblatt, T. W. Smith, and J. Koch-Weser. Bioavailability of drugs: the digoxin dilemma.Clin. Pharmacokin. 1:36–51 (1976).
J. G. Wagner, M. Christensen, E. Sakmar, D. Blair, J. D. Yates, P. W. Willis, A. J. Sedman, and R. G. Stoll. Equivalence lack in digoxin plasma levels.J. Am. Med. Assoc. 224:199–204 (1973).
J. W. Culbertson, R. W. Wilkins, F. J. Ingelfinger, and S. E. Bradley. The effect of the upright posture upon hepatic blood flow in normotensive and hypertensive subjects.J, Clin. Invest. 30:305–311 (1951).
D.F. Smith and M. Shimizu. Effect of posture on renal lithium clearance.Clin. Sci. Mol. Med. 51:103–105 (1976).
D. H. Huffman and D. L. Azarnoff. Absorption of orally given digoxin preparations.J. Am. Med. Assoc. 222:957–960 (1972).
F. Keller, H. P. Blumehthal, K. Maertin, and N. Rietbrock. Overall pharmacokinetics during prolonged treatment of healthy volunteers with digoxin andΒ-methyldigoxin.Eur. J. Clin. Pharmacol. 12:387–392 (1977).
M. H. Gault, D. Sugden, C. Maloney, M. Ahmed, and M. Tweeddale. Biotransformation and elimination of digoxin with normal and minimal renal function.Clin. Pharmacol. Ther. 25:499–513 (1979).
T. P. Gibson and H. A. Nelson. The question of cumulation of digoxin metabolites in renal failure.Clin. Pharmacol. Ther. 27:219–223 (1980).
F. J. Frey, B. M. Frey, A. Greither, and L. Z. Benet. Inequality of prednisolone clearance values obtained by iv bolus and by steady-state infusion.Clin. Res. 28(2): 236A (1980).
J. G. Wagner, R. G. Stoll, D. J. Weidler, J. W. Ayres, M. R. Hallmark, E. Sakmar, and A. Yacobi. Comparison of thein vitro andin vivo release of digoxin from four different soft gelatin capsule formulations.J. Pharmacokin. Biopharm. 7:147–158 (1979).
K. C. Kwan and A. E. Till. Novel method for bioavailability assessment. J. Pharm. Sci.62:1494–1497 (1973).
S. Øie and D. Jung. Bioavailability under variable renal clearance conditions.J. Pharm. Sci. 68:128–129 (1979).
Author information
Authors and Affiliations
Additional information
This work was supported in part by National Institutes of Health Grant 1 R01 HL 23862-01 and in part by National Institutes of Health General Clinical Research Center Grant 5M01 RR421.
Rights and permissions
About this article
Cite this article
Wagner, J.G., Popat, K.D., Das, S.K. et al. Evidence of nonlinearity in digoxin pharmacokinetics. Journal of Pharmacokinetics and Biopharmaceutics 9, 147–166 (1981). https://doi.org/10.1007/BF01068079
Received:
Revised:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF01068079